Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015

Sikhulile Moyo1,2,*, Simani Gaseitsiwe1,2, Terence Mohammed1, Molly Pretorius Holme1,2, Rui Wang3,4,5, Kenanao Peggy Kotokwe1, Correthah Boleo1, Lucy Mupfumi1, Etienne Kadima Yankinda1, Unoda Chakalisa1, Erik van Widenfelt1, Tendani Gaolathe1, Mompati O. Mmalane1, Scott Dryden-Peterson1,2,6, Madisa Mine1, Refeletswe Lebelonyane1, Kara Bennett6, Jean Leidner9, Kathleen E. Wirth2,10, Eric Tchetgen Tchetgen4,10, Kathleen Powis1,2,6,11, Janet Moore12, William A. Clarke13, Shahin Lockman1,2,5,6, Joseph M. Makhema1,2, Max Essex1,2, Vlad Novitsky1,2

1 Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana, 2 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, 3 Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America, 4 Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, 5 Harvard Medical School, Boston, Massachusetts, United States of America, 6 Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, 7 Botswana Ministry of Health and Wellness, Gaborone, Botswana, 8 Bennett Statistical Consulting, Inc., Ballston Lake, New York, United States of America, 9 Goodtables Data Consulting, Norman, OK, United States of America, 10 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, 11 Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 12 U.S. Centers for Disease Control, Atlanta, Georgia, United States of America, 13 Johns Hopkins Hospital, Baltimore, MD, United States of America

* sikhulilemoyo@gmail.com

Abstract

Background

Botswana is close to reaching the UNAIDS “90-90-90” HIV testing, antiretroviral treatment (ART), and viral suppression goals. We sought to determine HIV incidence in this setting with both high HIV prevalence and high ART coverage.

Methods

We used a cross-sectional approach to assessing HIV incidence. A random, population-based sample of adults age 16–64 years was enrolled in 30 rural and peri-urban communities as part of the Botswana Combination Prevention Project (BCPP), from October 2013 – November 2015. Data and samples from the baseline household survey were used to estimate cross-sectional HIV incidence, following an algorithm that combined Limiting-Antigen Avidity Assay (LAg-Avidity EIA), ART status (documented or by testing ARV drugs in plasma) and HIV-1 RNA load. The LAg-Avidity EIA cut-off normalized optical density (ODn) was set at 1.5. The HIV-1 RNA cut-off was set at 400 copies/mL. For estimation purposes,
the manuscript. The specific roles of these authors and analysis, decision to publish, or preparation of additional role in the study design, data collection KB and JL respectively, but did not have any on sharing data and material.

Competing interests: Kara Bennett is employed by Bennett Statistical Consulting, Inc and Jean Leidner was employed by Goodtables Data Consulting. The entities above provided support in the form of salaries for authors Kara Bennett and Jean Leidner, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Funding: This study was supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement U01 GH000447 to SM, SG, TM, MPH, EKY, UC, EKW, TG, MOM, RL, KEW, ETT, JM, SL, JMM, ME, and VN. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies. SM was supported by the Fogarty International Center and National Institute of Mental Health, of the National Institutes of Health under Award Number D43 TW010543. SM, SG and LM were partially funded by Wellcome Trust DELTAS Initiatives/Sub-Saharan Africa Network for TB/HIV Research Excellence (SANTHE) (107752/Z/15/Z). SDP was funded by the National Institutes of Health under the award K23AI091434. RW was supported by R37 AI51164 from the National Institutes of Health. The funders had no role in the study design, data collection and decision to publish, or in the preparation of the manuscript. Additionally, Bennett Statistical Consulting Inc. and Goodtables Data Consulting provided support in the form of salaries for authors KB and JL respectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: Kara Bennett is employed by Bennett Statistical Consulting, Inc and Jean Leidner was employed by Goodtables Data Consulting. The entities above provided support in the form of salaries for authors Kara Bennett and Jean Leidner, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Introduction
Botswana has been hard hit by the HIV-epidemic, with the third highest HIV prevalence worldwide among adults age 15–49, after Lesotho and Swaziland [1]. Botswana appears to be approaching the UNAIDS “90-90-90” HIV testing, treatment, and viral suppression targets [2]. These high levels of coverage have led to significant reductions in HIV-related mortality [1, 3–5]. In June 2016 Botswana adopted the World Health Organization (WHO) recommendation to provide Universal Test and Treat (UTT) [6]. The success of UTT could be measured by reduction in HIV incidence [7–25]. Monitoring of HIV incidence is a critical tool for assessment and evaluation the impact of HIV prevention and treatment programs.

Prospective longitudinal cohorts remain the gold standard for assessing HIV incidence. However, this approach is time consuming, costly and prone to selection and observational biases [8, 26]. Biomarkers of recent HIV infection that can be detected in cross-sectional samples represent a viable alternative to longitudinal cohort studies. Serological and molecular biomarkers could be combined in multi-assay algorithm (MAA). An optimized MAA with high sensitivity and specificity can discriminate between recent and established HIV infections in cross-sectional sample [27–29][8, 9, 25, 30–36]. Recent advances in design and development of MAA have facilitated estimating of HIV incidence in cross-sectional surveys with improved accuracy [7, 16, 22, 37].

In this study, we estimated HIV incidence using a baseline cross-sectional sample from the Botswana Combination Prevention Project (BCPP; the Ya Tsie study) [2, 38, 39]. BCPP is an
ongoing pair-matched, cluster-randomized clinical trial in 30 rural and peri-urban communities across Botswana. The primary question of the study is reduction in the cumulative HIV incidence as a result of combination prevention interventions that included enhanced HIV testing and counseling (HTC) campaigns, linkage to care, antiretroviral treatment (ART), strengthened male circumcision (MC) and enhanced prevention of mother-to-child transmission of HIV. Between October 2013 and November 2015, we selected a random sample from 30 communities in three main geographic areas in Botswana: (1) south east, (2) north east, and (3) central eastern region. The communities were purposively selected and proposed based on (1) desired size, and (2) feasibility. Pairs of communities were matched by size, health services, population age structure, and geographic location. In each community, a complete list of all household-like structures (located within the prespecified community boundaries as defined by the 2011 Botswana Census) was obtained and geocoded using satellite imagery (Google Earth, Mountain View, CA, USA). Based on these lists, a simple random sample of approximately 20% of all households was drawn. At each selected household all household members were enumerated, assessed for eligibility, and approached for participation [2]. The vast majority of HIV-positive participants of the baseline household survey, 83%, knew their HIV status [2], 87% of them were receiving ART [2], and 96% of those on ART were virologically suppressed [2].

Materials and methods

Study participants

Blood specimens were collected during the BCPP baseline household survey. The HIV-positive status of participants was based on either written documentation provided (e.g., HIV test results, ART prescription) or HIV testing that was performed in the households according to the Botswana national guidelines by using double positive rapid HIV testing. Participants who self-reported not being on ART and classified as recently infected by the MAA were tested for presence of ARV drugs in their plasma. In addition to HTC, the survey staff provided point-of-care CD4 testing, collected blood from people living with HIV for viral load testing and viral genotyping (venous blood was collected by phlebotomy in households), evaluated uptake of HTC, and assessed ART and MC coverage.

Among 12,610 individuals participating in the baseline household survey, HIV status was available for 12,570 participants and 3,596 of them were HIV positive. The study was conducted in accordance with the Declaration of Helsinki. The study received institutional review board approval from the Botswana Health Research Development Committee and the U.S. Centers for Disease Control and Prevention. All participants provided written informed consent. Participants aged 16–18 years provided written assent (with parents or guardians providing written permission). The study is registered at ClinicalTrials.gov (NCT01965470).

Limiting Antigen Avidity assay and HIV recent infection algorithm

All plasma specimens from HIV-positive individuals who participated in the survey were tested using the Sedia HIV-1 Limiting Antigen (LAg)-Avidity EIA (Sedia Biosciences Corporation, Portland, OR, USA) according to manufacturer’s instructions [40]. The LAg-Avidity EIA differentiates between ‘recent’ and long-term HIV infection. A normalized optical density (ODn) of <1.5 was considered to represent recent infection [36]. ART status was verified through documentation provided by the participants or testing for presence of ARV drugs in plasma. The MAA [25] included the following steps: (1) plasma specimens from HIV-positive individuals were tested by LAg-Avidity EIA following manufacturer’s recommendations, and ODn was calculated; (2) cases with ODn ≤1.5 were checked for ART status and individuals on ART were excluded from HIV recency candidates; (3) levels of HIV-1 RNA were checked for
the remaining candidates and individuals with undetectable viral load (≤400 copies/mL) were excluded from HIV recency candidates; and (4) HIV-positive individuals with ODn ≤1.5 in LAg-Avidity EIA, not taking ARV and having HIV-1 RNA >400 copies/mL were considered recently infected with HIV. Fig 1 shows the MAA applied for the cross-sectional HIV incidence estimation in BCPP. The MAA used the LAg-Avidity EIA in combination with testing for ARV and HIV-1 RNA load. The final sample of recently HIV infected individuals was identified based on HIV-positive status, ODn ≤1.5 in LAg-Avidity EIA, no use of ARVs and detectable viral load (HIV-1 RNA >400 copies/mL) at the time of testing.
**HIV-1 RNA quantification**

The HIV-1 RNA load in plasma was quantified by Abbott m2000sp/Abbott m2000rt (Wiesbaden, Germany). HIV-1 RNA >400 copies/mL was considered detectable viral load.

**ARV drug testing**

Plasma samples from participants who were classified as recently infected and had undetectable viral load (≤400 copies/mL) were screened for ARV drugs by high-throughput liquid chromatography coupled with Q-Exactive high-resolution mass spectrometry using data-dependent fragmentation and selected reaction monitoring at resolution of 17,500 [41]. To obtain qualitative results, each specimen was compared to positive and negative controls for each drug (abacavir, amprenavir, atazanavir, darunavir, efavirenz, emtricitabine, indinavir, lamivudine, lopinavir, maraviroc, nelfinavir, nevirapine, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, tipranavir, and zidovudine). The limit of identification ranged from 5 to 10 ng/ml for most drugs and is presented elsewhere [41].

**Statistical analysis and estimation of HIV incidence**

The annualized HIV incidence and 95% confidence intervals (CI) were estimated based on cross-sectional incidence assay-based methods that entail biomarkers of HIV disease progression that can distinguish recent from long-term infections [7, 14, 42–44]. Specifically, the annual incidence was estimated as follows:

\[
\hat{I} = \frac{n_R - \hat{\beta}_T T}{n_s (\hat{\Omega}_T - \hat{\beta}_T T)},
\]

Where \(n_R\), \(n_s\), and \(n\) represents the number of individuals who were classified as recent infection, who were HIV-positive (including both recent and non-recent infections), and who were uninfected, in the cross-sectional sample, respectively. \(\hat{\Omega}_T\) is the mean duration of recent infection (MDRI), which is the population average time spent in the ‘recent’ state; and \(\hat{\beta}_T\) is the false-recent rate (FRR), representing the proportion of subjects who had been infected for longer than time T (set to be 730 days) but were misclassified as recent infections. MDRI was set to 130 days with a standard error of 5.98 days, corresponding to an ODn threshold of 1.5 [36, 45]. Using HIV-1 RNA load measurement and excluding 14 virologically suppressed individuals from recency candidates justified setting the false-recent rate (FRR) at zero [25, 46]. Missing LAg-Avidity EIA test results were considered missing completely at random. Confidence intervals were estimated taking into account of clustering of communities by applying a design effect to both HIV prevalence and proportion of recent infections among HIV positive individuals, implemented in the R package IncTools v. 1.0.10 [44]. The IncTools implements the HIV incidence calculations from cross-sectional surveys following the guidelines as proposed by the WHO Incidence assays technical working group [23–25, 47].

In addition to estimating HIV incidence among 16–64 years old participants, we assessed HIV incidence in a subset of younger participants in order to compare our results with other studies in Botswana. Specifically, we estimated HIV incidence in a subset of 16–49 years old participants (n = 10,164) including 2,798 HIV-positive and 7,366 HIV-negative individuals.

**Results**

A total of 3,596 (29%) individuals from 30 communities in Botswana were HIV positive among 12,570 adults 16–64 years old with definitive HIV status during the baseline household
survey of the BCPP from 2013 to 2105 [2]. Table 1 presents basic socio-demographic and clinical characteristics of individuals participating in the baseline household survey. The median (IQR) age was 40 (33–48) years. The majority of participants were females (73%). Among HIV-positive participants, 3,581 (99.6%) were tested by the LAg-Avidity EIA.

A subset of 326 participants were classified as LAg-Avidity EIA-recent HIV infections with $\text{OD}_n \leq 1.5$ (Fig 1). The documented ART status was considered as an indicator of long-term HIV infection, and 278 of 326 participants were excluded from recency candidates due to being on ART. A subset of 14 individuals who reported no prior use of ART (including 3 cases with detected ARV drugs in plasma) had undetectable HIV-1 RNA load ($\leq 400$ copies/mL), were excluded from the pool of individuals classified as recent HIV-infection [46]. Three of 14 individuals with undetectable viral load and reporting no prior ART use had ARVs in plasma that were the first-line treatment regimens most commonly prescribed in Botswana’s national ART program at the time of sampling: two cases of zidovudin/3TC/efavirenz and one case of zidovudin/3TC/nevirapine. Thus, 34 LAg-Avidity EIA-recent and ARV-naïve participants with detectable HIV-1 RNA load were classified as recent HIV infections (Fig 1). The estimate of annualized HIV incidence is 1.06% (95% CI 0.68–1.45%), assuming an FRR of zero. For a more conservative estimate, we used the adjusted FRR at 0.39% that was determined in our recent study in Botswana [48], and estimated the annualized HIV incidence at 0.64% (95% CI 0.24–1.04%). A higher proportion of recent infections were among young participants, less than 30 years of age (Table 1).

All recently infected individuals ($n = 34$) were younger than 49 years old. The annualized HIV incidence in the subset of 16–49 years old individuals was estimated at 1.29% (95% CI 0.82–1.77%) with FRR set to zero, and at 0.90% (95% CI 0.42–1.38%) with FRR set to 0.39%. For comparison, two alternative published estimates of HIV incidence in Botswana including UNAIDS [49] are presented in Table 2 along with results of this study.

Discussion

HIV incidence in a population-based sample of adults 16–64 years old residing in 30 communities across Botswana was estimated at about 1% from cross-sectional sampling that occurred
in 2013–2015. Estimated HIV incidence was slightly higher (0.90–1.29%, depending on the FRR) in a subset of younger 16–49-year-old adults. Results of our study corroborate the recent UNAIDS estimates of HIV incidence in Botswana (0.93%) [49], and suggest a declining trend from previously estimated HIV incidence among 15–49 year old adults in Botswana (3.5% in 2000, 2.4% in 2007 and 1.7% in 2008 [51]). Our results support the observation that new HIV infections across sub-Saharan Africa continue to decline, although HIV incidence in Botswana remains unacceptably high [52].

The strength of the current estimate of HIV incidence includes population-based random sampling from 30 rural and peri-urban communities across the country, and application of MAA that includes LAg-Avidity EIA, ART status, and measurements of HIV-1 RNA in all HIV-positive participants. Limitations of our study include MAA that is reliant upon the ART status and the uncertainty arising from estimates of corresponding FRR and MDRI. In our previous studies, we have also found similar estimates of MDRI using an MAA with ART status and viral load [53]. Individuals on ART were excluded from recency candidates, because being on ART was interpreted as an indicator of longstanding HIV infection. This approach worked well in the era of CD4-driven initiation of ARV therapy, and was in line with the Botswana HIV treatment guidelines at the time of sampling, 2013 to 2015. In June 2016 Botswana introduced a new national policy “Treatment for All”, that is, initiating ART as soon as possible regardless of CD4+ T-cell counts [6]. The ongoing scaling up of this national policy means that ART status cannot be used as exclusion criteria for estimation of HIV recency in future studies. Novel cross-sectional assays and MAA independent of ART status are needed to address this issue.

Self-reported ART status could be considered one of the study limitations. Although ART status was verified through documentation among those who self-reported to be on ART, there is an uncertainty due to possible undisclosed ART use among those who self-reported not to be on ART. To address this limitation we performed ARV drug testing in plasma among those who had undetectable levels of HIV-1 RNA and reported no ART use. In fact, we found triple ARV drugs in 3 out of 14 cases. Using viral load threshold could minimize uncertainty of self-reported status. In fact, 3 cases with ARV drugs in plasma were excluded based on low levels of HIV-1 RNA.

While we used a Botswana-specific FRR from our previous study [48], it was estimated in a cohort sampled approximately a decade before sampling in the current study. We speculate that FRR in Botswana could be decreasing over time and could be lower than the 0.39% used for conservative estimates of HIV incidence in this study. The extent to which regional FRRs are changing over time remains unknown. The scale up of national ART programs could affect FRR estimates. Since ART guidelines have been changing, a greater proportion of individuals

Table 2. Estimates of annualized HIV-1 incidence in Botswana.

| Estimate Source | Year | Age group (years) | Point estimate, % | 95% CI |
|-----------------|------|------------------|------------------|-------|
| UNAIDS modeling [49] | 2016 | 15–49 | 0.93 | 0.68–1.18 |
| MAA, LAg-Avidity EIA, FRR = 0, this study | 2013–2015 | 16–64 | 1.06 | 0.68–1.45 |
| MAA, LAg-Avidity EIA, FRR = 0.39%, this study | 2013–2015 | 16–64 | 0.64 | 0.24–1.04 |
| MAA, LAg-Avidity EIA, FRR = 0, this study | 2013–2015 | 16–49 | 1.29 | 0.82–1.77 |
| MAA, LAg-Avidity EIA, FRR = 0.39%, this study | 2013–2015 | 16–49 | 0.90 | 0.42–1.38 |
| AIDS Impact Survey IV, BED, FRR = 2.98 [50] | 2012 | 1.5+ | 1.35 | 0.43–2.27 |

Abbreviations. UNAIDS: Joint United Nations Program on HIV/AIDS. MAA: Multi-Assay Algorithm including viral load (400 copies/mL cut-off) and documented HIV status. LAg-Avidity EIA: Limiting Antigen–Avidity EIA. BED–BED Incidence Assay. FRR: False Recent Rate; CI–Confidence Intervals.

https://doi.org/10.1371/journal.pone.0204840.t002
are initiating treatment sooner, more frequently soon after HIV diagnosis. This means the increasing ART coverage could reduce FRR. In this manuscript, the MAA algorithm included ARV drug testing leading to reduction of FRR to zero. However, uncertainty remains as to whether FRR can be eliminated [47]. The upper range of FRR then is FRR without drug tracing, as we determined in our previous study in Botswana [48, 54].

The relatively high estimated HIV incidence that we found (~1%) despite high levels of HIV testing, treatment, and viral suppression may reflect several factors. First, the impact of widespread ART on HIV incidence may take several years to be realized. In addition, the ~30% of HIV-infected individuals with detectable viremia [2] could yield such high HIV incidence in the setting of very high HIV prevalence (and these individuals could have different HIV risk behavior, compared with those with viral suppression on ART). Our findings highlight the importance of targeted interventions to reach individuals who have not yet sought HIV testing or treatment services.

Conclusion

In summary, using cross-sectional sampling and MAA based on LAg-Avidity EIA, ART status (either documented or by testing ARV drugs in plasma) and HIV-1 RNA measurements, we estimated the HIV incidence in 30 rural and peri-urban Botswana communities in 2013–2015 at about 1%. A higher proportion of recent infections were among participants less than 30 years of age. A reduction from this relatively high estimated HIV incidence may take several years to be realized despite the impact of widespread ART and other on-going interventions. Targeted interventions are required to reach individuals who have not yet sought HIV testing or treatment services.

Acknowledgments

We thank the study participants. We are grateful to the entire BCPP staff including the field study teams for making this study a success. We thank the BCPP team members for their contribution to this study: Ngozana Seonyatseng, Tumalano Sekoto Pharatlhatlhe, Vinolia Simon, Rona Letlhogile, Atang Mbikiwa, Kutlo Manyake, Neo Mogowa, Moemedi Tshwenyana, Kagiso Watema, Chebukani Nkobodo, Phelimon Pong Sebogodi, Thabani Ncube, Dineo Mongwato, Coulsen Kgathi, Thuso Mokane, Kutlwano Mukokomani, Mompati Mmalanwe, Mada Ria, Madison, Chloe Auletta-Young, Botswana Harvard HIV Reference Laboratory Staff, Data Management Centre Staff, and field laboratory assistants. We thank Lendsey Melton for excellent editorial assistance. We thank Michelle Roland for helpful critique and discussion. We would like to thank Reshma Kassanjee, Alex Welte and Eduard Grebe for useful discussions in the application of cross-sectional methods and use of IncTools.

Author Contributions

Conceptualization: Sikhulile Moyo, Molly Pretorius Holme, Eric Tchetgen Tchetgen, Shahin Lockman, Joseph M. Makhema, Max Essex, Vlad Novitsky.

Formal analysis: Sikhulile Moyo, Simani Gaseitsiwe, Vlad Novitsky.

Funding acquisition: Shahin Lockman, Max Essex.

Investigation: Sikhulile Moyo, Simani Gaseitsiwe, Terence Mohammed, Molly Pretorius Holme, Rui Wang, Kenanao Peggy Kotokwe, Corretah Boleo, Lucy Mupfumi, Etienne Kadima Yankinda, Unoda Chakalisa, Erik van Widenfelt, Tendani Gaolathe, Mompati O.
Methodology: Sikhulile Moyo, Rui Wang, Refeletswe Lebelonyane, Kathleen E. Wirth, William A. Clarke, Shahin Lockman, Joseph M. Makhema, Max Essex, Vlad Novitsky.

Project administration: Simani Gaseitsiwe, Etienne Kadima Yankinda, Unoda Chakalisa, Tendani Gaolathe, Mompati O. Mmalane, Refeletswe Lebelonyane, Janet Moore, Joseph M. Makhema.

Supervision: Simani Gaseitsiwe, Terence Mohammed, Molly Pretorius Holme, Lucy Mupfumi, Etienne Kadima Yankinda, Unoda Chakalisa, Erik van Widenfelt, Tendani Gaolathe, Mompati O. Mmalane, Kathleen E. Wirth, Eric Tchetgen Tchetgen, Kathleen Powis, Janet Moore, Shahin Lockman, Joseph M. Makhema, Max Essex, Vlad Novitsky.

Writing – original draft: Sikhulile Moyo, Vlad Novitsky.

Writing – review & editing: Sikhulile Moyo, Simani Gaseitsiwe, Terence Mohammed, Molly Pretorius Holme, Rui Wang, Kenanao Peggy Kotokwe, Corretah Boleo, Lucy Mupfumi, Etienne Kadima Yankinda, Unoda Chakalisa, Erik van Widenfelt, Tendani Gaolathe, Mompati O. Mmalane, Scott Dryden-Peterson, Madisa Mine, Refeletswe Lebelonyane, Kara Bennett, Jean Leidner, Kathleen E. Wirth, Eric Tchetgen Tchetgen, Kathleen Powis, Janet Moore, Shahin Lockman, Joseph M. Makhema, Max Essex, Vlad Novitsky.

References
1. UNAIDS. 90-90-90 On the right track towards the global target. URL http://www.cfenet.ubc.ca/sites/default/files/uploads/IAS2016/90_90_90_Progress_ReportFINAL.pdf. 2016.
2. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana’s progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016; 3(5):e221–30. https://doi.org/10.1016/S2352-3018(16)00037-0 PMID: 27126489.
3. UNAIDS. Global AIDS Update 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf. 2016.
4. UNAIDS, UNAIDS Data 2017 http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf. 2017.
5. UNAIDS. GLOBAL AIDS RESPONSE PROGRESS REPORTING 2015 http://www.unaids.org/sites/default/files/media_asset/JC2702_GARPR2015guidelines_en.pdf. 2015.
6. World Health Organisation. Botswana Launches Treat All Strategy. 2016. Available from: http://www.afro.who.int/news/botswana-launches-treat-all-strategy.
7. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995; 141(2):166–72. PMID: 7817972.
8. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol. 2013; 177(3):264–72. https://doi.org/10.1093/aje/kws436 PMID: 23302151; PubMed Central PMCID: PMC3626051.
9. Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013; 63 Suppl 2:S233–9. https://doi.org/10.1097/QAI.0b013e31829896ef PMID: 23764641; PubMed Central PMCID: PMC373794.
10. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. Jama. 2008; 300(5):520–9. https://doi.org/10.1001/jama.300.5.520 PMID: 18677024; PubMed Central PMCID: PMC2919237.
11. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998; 280(1):42–8. PMID: 9660362.
12. Hargrove JW, Humphrey JH, Mutasa K, Parekh BS, McDougal JS, Ntsozini R, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS. 2008; 22(4):511–8. Epub 2008/
13. McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, Ackers M, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses. 2006; 22 (10):945–52. Epub 2006/10/28. https://doi.org/10.1089/aid.2006.22.945 PMID: 17067263.

14. McDougal JS, Pilcher CD, Parekh BS, Gershoy-Damet G, Branson BM, Marsh K, et al. Surveillance for HIV-1 incidence using tests for recent infection in resource-constrained countries. AIDS. 2005; 19 Suppl 2:S25–30. PMID: 15930838.

15. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, et al. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses. 2011; 27(3):265–73. https://doi.org/10.1089/aid.2010.0159 PMID: 20954834.

16. Parekh BS, Kennedy MS, Dobbs TL, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. The Indian journal of medical research. 2005; 121(4):510–8. Epub 2005/04/09. PMID: 15817960.

17. Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. The PLoS One. 2012; 7(11):e49661. https://doi.org/10.1371/journal.pone.0049661 PMID: 23166743; PubMed Central PMCID: PMC3500513.

18. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G, Rodriguez W, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS. 2010; 24(18):2763–71. https://doi.org/10.1097/QAD.0b013e32833f1142 PMID: 20975514.

19. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, Laeyendecker O, et al. Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. J HIV AIDS Survell Epidemiol. 2010; 2(1):1–14. PMID: 21743821; PubMed Central PMCID: PMC3130510.

20. Kassanjee R, McWallter TA, Barnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology. 2012; 23(5):721–8. https://doi.org/10.1097/EDE.0b013e3182576cd7 PMID: 22627902; PubMed Central PMCID: PMC3500970.

21. Rosenberg NE, Pilcher CD, Busch MP, Cohen MS. How can we better identify early HIV infections? Curr Opin HIV AIDS. 2014. Epub 2014/11/13. https://doi.org/10.1097/coh.0000000000000121 PMID: 25389806.

22. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, Laeyendecker O, et al. Estimating HIV incidence in populations using tests for recent infection: issues, challenges and the way forward. Journal of HIV AIDS surveillance & epidemiology. 2010; 2(1):1.
30. Eshleman SH, Hughes JP, Laeyendecker O, Wang J, Brookmeyer R, Johnson-Lewis L, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013; 207(2):223–31. https://doi.org/10.1093/infdis/jis658 PMID: 23129758; PubMed Central PMCID: PMC3532822.

31. Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, et al. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS One. 2013; 8(12):e82772. https://doi.org/10.1371/journal.pone.0082772 PMID: 24386116; PubMed Central PMCID: PMC3873916.

32. Laeyendecker O, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, et al. HIV incidence determination in the United States: a multiasay approach. J Infect Dis. 2013; 207(2):232–9. https://doi.org/10.1093/infdis/jis659 PMID: 23129760; PubMed Central PMCID: PMC3532826.

33. Laeyendecker O, Brookmeyer R, Mullis C, Donnell D, Lingappa J, Celum C, et al. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: Analysis of samples from adults with known non-recent HIV infection from five African countries. AIDS Res Hum Retroviruses. 2012. Epub 2012/01/31. https://doi.org/10.1089/AID.2011.0341 PMID: 22835149.

34. Laeyendecker O, Kulich M, Donnell D, Komarek A, Omelka M, Mullis CE, et al. Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. PLoS One. 2013; 8(11):e78818. https://doi.org/10.1371/journal.pone.0078818 PMID: 24236054; PubMed Central PMCID: PMC3827276.

35. Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One. 2013; 8(7):e68349. https://doi.org/10.1371/journal.pone.0068349 PMID: 23874597; PubMed Central PMCID: PMC3708944.

36. Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the Limiting Antigen Avidity EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes. PLoS One. 2015; 10(2):e0114947. https://doi.org/10.1371/journal.pone.0114947 PMID: 25710171; PubMed Central PMCID: PMC4339840.

37. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, et al. Development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014; 433:157–68. Epub 2014/03/26. https://doi.org/10.1016/j.cca.2014.03.016 PMID: 24661980; PubMed Central PMCID: PMCPMC4039613.

38. Novitsky V, Prague M, Moyo S, Gaolathe T, Mmalane M, Kadima Yankinda E, et al. High HIV-1 RNA among Newly Diagnosed People in Botswana. AIDS Res Hum Retroviruses. 2017. https://doi.org/10.1089/aid.2017.0214 PMID: 29214845.

39. Novitsky V, Gaolathe T, Mmalane M, Moyo S, Chakalisa U, Kadima Yankinda E, et al. Lack of Virological Suppression among Young HIV-Positive Adults in Botswana. JAIDS. 2018 [In Press].

40. Duong YT, Oiu M, De AK, Jackson K, Dobbs T, Kim AA, et al. Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies. PLoS One. 2012; 7(3):e33328. Epub 2012/04/06. https://doi.org/10.1371/journal.pone.0033328 PONE-D-11-24174 [pii]. PMID: 22479384.

41. Marzinke MA, Breaud A, Parsons TL, Cohen MS, Piwowar-Manning E, Eshleman SH, et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014; 433:157–68. Epub 2014/03/26. https://doi.org/10.1016/j.cca.2014.03.016 PMID: 24661980; PubMed Central PMCID: PMCPMC4039613.

42. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995; 141(2):166–72. PMID: 7817972.

43. Wang R, Lagakos SW. On the use of adjusted cross-sectional estimators of HIV incidence. J Acquir Immune Defic Syndr. 2009; 52(5):538–47. Epub 2009/11/03. https://doi.org/10.1097/QAI.0b013e3181c080a7 [doi]. PMID: 19861357.

44. Welte A, Grebe E, McIntosh A, Bäumler P, Kassanjee R, Brand H, et al. incitools: Incidence Estimation Tools. http://www.incidence-estimation.org/page/incitools. 2017.

45. Moyo S, Mohammed T, Kotokwe K, Boelo C, Mupfumi L, Gaseitsiwe S, et al. Cross-sectional estimates of HIV incidence remain high in rural communities in Botswana in the era of successful scale-up of ART. Abstract TUPDC0103. IAS2016.

46. Rehle T, Johnson L, Hallett T, Mahy M, Kim A, Odoi H, et al. A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods. PLoS One. 2015; 10(7):e0133255. https://doi.org/10.1371/journal.pone.0133255 PMID: 26230949; PubMed Central PMCID: PMC4521952.
47. World Health Organization. Technical update on HIV incidence assays for surveillance and monitoring purposes. Geneva: World Health Organization Copyright (c) World Health Organization; 2015. Available from: http://www.who.int/hiv/pub/surveillance/technical-update-incidence/en/.

48. Moyo S, Kotokwe KP, Mohammed T, Boleo C, Mupfumi L, Chishala S, et al. Low False Recent Rate of Limiting Antigen-Avidity Assay Combined with HIV-1 RNA Data in Botswana. AIDS Res Hum Retroviruses. 2017; 33(1):17–8. https://doi.org/10.1089/AID.2016.0127 PMID: 27481530.

49. UNAIDS. Country factsheets. BOTSWANA 2016. http://www.unaids.org/en/regionscountries/countries/botswana 2017.

50. Central Statistics Office. Botswana AIDS Impact Survey IV—2013. Gaborone: Republic of Botswana; 2014. Available from: http://www.statsbots.org.bw/sites/default/files/publications/Botswana AIDS Impact Survey Summary Apr 2014.pdf.

51. Stover J, Fidzani B, Molomo BC, Moeti T, Musuka G. Estimated HIV trends and program effects in Botswana. PLoS One. 2008; 3(11):e3729. https://doi.org/10.1371/journal.pone.0003729 PMID: 19008957; PubMed Central PMCID: PMCPMC2579326.

52. Kharsany AB, Karim QA. HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J. 2016; 10:34–48. Epub 2016/06/28. https://doi.org/10.2174/1874613601610010034 PMID: 27347270; PubMed Central PMCID: PMCPMC4893541.

53. Moyo S, Vandormael A, Wilkinson E, Engelbrecht S, Gaseitsiwe S, Kotokwe KP, et al. Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana. PLoS One. 2016; 11(8): e0160649. https://doi.org/10.1371/journal.pone.0160649 PMID: 27552218.

54. World Health Organization. Foundation for Innovative New Diagnostics, WHO Working Group on HIV Incidence Assays. Meeting report, Boston, MA, USA, 20–26 February 2016. Geneva: World Health Organization; 2017. Available from: http://apps.who.int/iris/bitstream/handle/10665/254868/WHO-HIV-2017.04-eng.PDF?sequence=1.